Drug Trial Radar · NCT07254871
Study of DM-101PX in Adults With Birch Pollen Allergy
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
97
Actual
Start
Sep 26, 2025
Primary completion
Apr 15, 2026
Study completion Aug 10, 2026
Sponsor
- Lead sponsor
- Desentum OyIndustry
- Sponsor type
- Industry
- First posted
- Nov 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Randomized, double-blind placebo-controlled phase 2 trial with the aim to investigate safety and efficacy of DM-101-PX in reducing allergic symptoms provoked by nasal allergen challenge in birch pollen allergic adults. Expanded access to the study treatment is not available.
Conditions
- Birch Pollen Allergy
Interventions
DM-101PXBiological
subcutaneous injection of DM-101PX
PlaceboBiological
Placebo to match DM-101PX administered subcutaneously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Total Nasal Symptom Score (TNSS) after treatmentTime frame: From baseline to 3 weeks after the last dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cliantha Research
Mississauga, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.